A landmark study has revealed that existing HIV drugs can effectively suppress the transmission of HTLV-1, a neglected virus impacting numerous First Nations communities globally. This discovery, published in Cell, opens doors for the first preventative treatments and potential cures for HTLV-1.
***
Key Findings: Suppressing and Eliminating HTLV-1 🤔
The research, conducted by WEHI and the Doherty Institute, demonstrated that two readily available HIV antivirals—tenofovir and dolutegravir—successfully suppressed HTLV-1 transmission in humanized mice. This offers a direct path to clinical trials, bypassing the need for lengthy drug development.
Furthermore, combining these antivirals with a compound that induces cell death proved effective in eliminating HTLV-1-infected cells, suggesting a potential curative strategy for those already infected.
***
Understanding HTLV-1 and its Impact 🔬
HTLV-1, like HIV, infects T cells, crucial components of the immune system. While many infected individuals remain asymptomatic, a subset develops severe diseases, including adult T-cell leukemia and spinal cord inflammation. Early intervention is crucial, as symptoms can take decades to appear, often resulting in irreversible immune damage by the time of diagnosis.
***
A Decade of Research: Humanized Mouse Models and Novel Insights 🐭
The study utilized a groundbreaking humanized mouse model, developed over 10 years, allowing researchers to study HTLV-1 in a living organism with a human-like immune system. This model was instrumental in studying the virus’s behavior and the impact of different strains, including the unique HTLV-1c strain prevalent in Australia.
The research revealed that both international (HTLV-1a) and Australian (HTLV-1c) strains caused disease in the mice, with HTLV-1c exhibiting more aggressive characteristics. Importantly, the identified drug therapies proved equally effective against both strains.
***
Advocacy, Collaboration, and the Path Forward 🤝
This research highlights the importance of advocacy for neglected diseases. Years of collaboration with NACCHO and the Australian Department of Health led to the WHO classifying HTLV-1 as a Threatening Pathogen, paving the way for international guidelines and clinical management strategies.
The research team is actively engaging with pharmaceutical companies to explore incorporating HTLV-1 patients into existing clinical trials for the HIV antivirals. This could lead to the first approved pre-exposure prophylaxis (PrEP) for HTLV-1, a significant advancement in preventing transmission and disease.
***
Conclusion: Hope for HTLV-1 Prevention and Treatment 🎉
This groundbreaking study offers a beacon of hope for individuals and communities affected by HTLV-1. The repurposing of existing, safe, and effective HIV drugs presents a rapid pathway towards preventing transmission and potentially curing this devastating virus. The results represent a major leap forward in the fight against HTLV-1, underscoring the power of collaborative research and persistent advocacy.
Source: A deadly virus no one talks about — and the HIV drugs that might stop it
